CNTB
Connect Biopharma Holdings Limited NASDAQ Listed Mar 19, 2021$2.19
-0.91%
vs $2.21
Mkt Cap $137.6M
52w Low $1.23
36.9% of range
52w High $3.82
50d MA $2.21
200d MA $2.41
P/E (TTM)
—
EV/EBITDA
—
P/B
2.9x
Debt/Equity
0.0x
ROE
-132.2%
P/FCF
-2.4x
RSI (14)
50.40
ATR (14)
$0.11
Beta
-0.21
50d MA
$2.21
200d MA
$2.41
Avg Volume
536.3K
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
East R&D Building · Taicang, CA 215400 · CN
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.30 | -0.27 | +10.0% | 2.62 | +1.5% | +3.8% | +9.9% | -4.3% | -1.4% | -6.7% | — |
| Aug 13, 2025 | AMC | -0.22 | -0.23 | -4.5% | 2.36 | -0.4% | -8.9% | -4.7% | -6.3% | -5.7% | -7.7% | — |
| Mar 31, 2025 | AMC | -0.27 | -0.06 | +78.7% | 0.55 | +14.5% | +4.0% | +10.2% | -6.4% | +6.8% | -4.7% | — |
| Sep 5, 2024 | AMC | -0.03 | 0.02 | +167.4% | 1.19 | -8.4% | +5.0% | +0.8% | +0.8% | -0.8% | -4.8% | — |
| Apr 16, 2024 | AMC | -0.03 | -0.07 | -131.8% | 1.73 | -4.6% | -10.4% | -1.9% | +1.3% | -12.3% | +3.0% | — |
| Sep 12, 2023 | AMC | -6.92 | -0.08 | +98.9% | 0.76 | -1.0% | +2.9% | +7.7% | -9.5% | -10.5% | +5.5% | — |
| Apr 11, 2023 | AMC | -3.58 | -0.15 | +95.8% | 1.14 | +2.6% | -1.8% | +0.9% | -7.1% | +3.8% | +4.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26 | Piper Sandler | Initiates | Overweight | $7 | $2.07 | $2.12 | +2.4% | +5.8% | +8.7% | +0.0% | +0.4% | +2.9% |
| May 26 | Canaccord Genuity | Initiates | Buy | $6 | $2.35 | $2.45 | +4.3% | +2.1% | +0.0% | -0.8% | +4.6% | -6.0% |
| May 21 | Cantor Fitzgerald | Initiates | Overweight | $4 | $2.31 | $2.36 | +2.2% | +2.2% | -0.4% | +2.1% | +0.0% | -0.8% |
| Apr 1 | BTIG | Maintains | Buy → Buy | — | $2.62 | $2.66 | +1.5% | +3.8% | +9.9% | -4.3% | -1.4% | -6.7% |
| Mar 31 | BTIG | Maintains | Buy → Buy | — | $2.90 | $2.78 | -4.1% | -9.7% | +3.8% | +9.9% | -4.3% | -1.4% |
| Nov 13 | BTIG | Maintains | Buy → Buy | — | $1.61 | $1.55 | -3.7% | +4.3% | +26.2% | +17.5% | +3.2% | +22.6% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.27 | $2.46 | +8.4% | +4.0% | -8.9% | -4.7% | -6.3% | -5.7% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.55 | $0.63 | +14.5% | +4.0% | +10.2% | -6.4% | +6.8% | -4.7% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.68 | $0.68 | +0.0% | -19.1% | +4.0% | +10.2% | -6.4% | +6.8% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.19 | $1.09 | -8.4% | +5.0% | +0.8% | +0.8% | -0.8% | -4.8% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.77 | $1.76 | -0.6% | -5.1% | -4.8% | +3.1% | -9.7% | -2.7% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.65 | -4.6% | -10.4% | -1.9% | +1.3% | -12.3% | +3.0% |
| Sep 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.76 | $0.75 | -1.0% | +2.9% | +7.7% | -9.5% | -10.5% | +5.5% |
| Feb 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $1.19 | $1.14 | -4.2% | -1.7% | -3.4% | -1.8% | -0.9% | -9.9% |
| May 5 | Piper Sandler | Downgrade | Overweight → Neutral | — | $0.82 | $0.80 | -2.4% | -14.6% | -10.7% | -10.2% | +4.3% | +6.8% |
| May 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $1.94 | $1.38 | -28.9% | -57.7% | -14.6% | -10.7% | -10.2% | +4.3% |
| Jan 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $5.00 | $4.50 | -10.0% | -7.0% | -0.9% | +2.0% | +4.9% | +3.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Huang James | — | Buy | 150,000 | $2.48 | $372K | 13,310,000 | +3.72% | -3.64% |
8-K · 8.01
!! High
Connect Biopharma Holdings Limited -- 8-K 8.01: Material Event / Announcement
Connect Biopharma's Data Monitoring Committee completed its interim efficacy review without recommending sample size changes, suggesting the trial is progressing as planned toward potential regulatory approval.
Apr 23
8-K
Unknown — 8-K Filing
Centaur Pharmaceuticals' lead drug shows promising early safety/efficacy data while securing $20.2M funding, extending runway and reducing near-term dilution concerns for investors betting on rademikibart's clinical success.
Mar 31
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CNTB/SMHGF agreed to sell shares through Leerink Partners, likely diluting existing shareholders but providing near-term capital for operations or debt reduction.
Mar 30
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Adar1 Capital Management, Llc | 742,400 | $2M | New | Mar 2026 |
| 2 | Millennium Management | 474,601 | $1M | Added | Mar 2026 |
| 3 | Bml Capital Management, Llc | 408,887 | $1M | — | Mar 2026 |
| 4 | Knott David M Jr | 387,835 | $1M | Added | Mar 2026 |
| 5 | Stonepine Capital Management, Llc | 310,000 | $812K | New | Mar 2026 |
| 6 | Susquehanna International Group, Llp | 278,808 | $730K | Added | Mar 2026 |
| 7 | Propel Bio Management, Llc | 209,493 | $554K | New | Mar 2026 |
| 8 | Richmond Brothers, Inc. | 173,485 | $489K | New | Dec 2025 |
| 9 | Renaissance Technologies Llc | 120,700 | $316K | Reduced | Mar 2026 |
| 10 | Jane Street Group, Llc | 82,226 | $232K | New | Dec 2025 |
| 11 | Citadel Advisors Llc | 76,074 | $199K | Reduced | Mar 2026 |
| 12 | Marshall Wace, Llp | 66,013 | $173K | Reduced | Mar 2026 |
| 13 | Koa Wealth Management, Llc | 49,600 | $140K | — | Dec 2025 |
| 14 | Two Sigma Investments, Lp | 47,465 | $124K | New | Mar 2026 |
| 15 | Royal Bank Of Canada | 40,400 | $106K | — | Mar 2026 |
| 16 | Point72 Asset Management | 19,766 | $52K | Added | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 15,673 | $41K | New | Mar 2026 |
| 18 | Hrt Financial Lp | 15,299 | $40K | Reduced | Mar 2026 |
| 19 | Morgan Stanley | 4,418 | $12K | Added | Dec 2025 |
| 20 | Jpmorgan Chase & Co | 121 | $351 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$137.6M
Enterprise Value
$78.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.01x
P/B
2.90x
P/S
4.89x
P/FCF
-2.38x
EV/EBITDA
—
Shares Out
55.7M
Financials (TTM)
Revenue
$24.9M
Net Income
-$22.1M
EBITDA
-$21.2M
Free Cash Flow
-$51.6M
Op Cash Flow
-$51.2M
EPS Basic
$-1.00
EPS Diluted
$-0.78
EPS Forward
$-0.88
Gross Margin
100.0%
Op Margin
-100.2%
Net Margin
-88.8%
Balance Sheet
Total Assets
$56.1M
Total Liab.
$14.1M
Total Equity
$42.0M
Cash
$44.3M
LT Debt
$0
Book Value/Sh
$0.75
Debt/Equity
0.02x
Current Ratio
3.74
Quick Ratio
3.74
Returns & Growth
ROE
-132.2%
ROA
-98.9%
ROIC
-135.7%
Rev Growth YoY
-99.8%
EPS Growth YoY
-257.1%
Price Returns
2W
+3.0%
1M
-0.7%
3M
-6.6%
6M
-9.3%
12M
+6.5%
Technicals
52W High
$3.82
52W Low
$1.23
50d MA
$2.21
200d MA
$2.41
RSI (14)
50.40
ATR (14)
$0.11
Beta
-0.21
Avg Volume
536K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$9.00
High
$9.00
Low
$9.00
Median
$9.00
Data updated apr 25, 2026 2:20am
· Source: financialmodelingprep.com